

PERSONAL INFORMATION

Cristian Turato



University of Pavia
Department of Molecular Medicine
Via Ferrata 9, 27100 Pavia



✉ cristian.turato@unipv.it

Date of birth 14/01/1981, Padova

WORK EXPERIENCE

04/2023-today- Associate Professor of General Pathology and Immunology (MED/04)
Department of Molecular Medicine, University of Pavia, Italy.

04/2020-03/2023- Researcher, Department of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Italy.

03/2017-03/2019 Post doc senior scientist, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.

03/2012-02/2017 Post doc senior scientist, Department of Medicine, Unit of Molecular Hepatology, University of Padova, Italy.

09/2009- 02/2012- Research fellow, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.

09/2006-08/2009 Research fellow, Unit of Molecular Hepatology, Department of Medicine, University of Padova, Italy.

EDUCATION

2011: Ph.D. in Clinical and Experimental Medicine, Department of Medicine, Molecular Hepatology Division, University of Padova. Italy.

2006: Master Degree in Medical Biotechnology, University of Padova. Italy

WORK ACTIVITIES

Editorial activity

Guest editor of "Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment" Molecular Oncology section. International Journal of Molecular Sciences.

Guest editor of "Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment" Molecular Pathology, Diagnostics, and Therapeutics" section. International Journal of Molecular Sciences.

Peer Reviewer for the following journals: Journal of Clinical and Experimental Hepatology, Cancer Biomarkers, Experimental Biology and Medicine, Life Sciences, Digestive and Liver Disease, Cancers, Biomedicines, International Journal of Molecular Sciences, Cell Death Discovery.

Patents

WO2018163119. Title: 1-piperidinepropionic acid for treating a fibrosing disease

ADDITIONAL INFORMATION

Link ORCID publications: <https://orcid.org/0000-0001-7086-0792>

Publications

List of major publications

Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.
De Siervi S, Turato C.
Int J Mol Sci. 2023 Feb 25;24(5):4529. doi: 10.3390/ijms24054529.

Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice.
Turkseven S, Turato C, Villano G, *et al.*
Antioxidants (Basel). 2023 Apr 21;12(4):971. doi: 10.3390/antiox12040971.

Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
Di Maira G, Foglia B, Napione L, Turato C, *et al.*
J Pathol. 2022 May;257(1):82-95. doi: 10.1002/path.5871.

Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells.
Cannito S, Bincoletto V, Turato C, *et al.*
Molecules. 2022 Feb 4;27(3):1062. doi: 10.3390/molecules27031062.

MiR-122 targets SerpinB3 and is involved in Sorafenib resistance in hepatocellular carcinoma
C Turato, F Fornari, D Pollutri, *et al.*
Journal of Clinical Medicine 2019 Feb 1;8(2). pii: E171. doi: 10.3390/jcm8020171.

SCCA1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity.
Turato C, Scarpa M, Kotsafti A, *et al.*
Cancer Sci. 2019 Mar 2. doi: 10.1111/cas.13986

New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C, Balasso A, Carloni V, *et al.*
J Control Release. 2017 Oct 16; 268:184-197. doi: 10.1016/j.jconrel.2017.10.027.

SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity.
Turato C, Cannito S, Simonato D, *et al.*
Sci Rep. 2015 Dec 4; 5:17701. doi: 10.1038/srep17701

SerpinB3 is associated with TGF- β 1 and cytoplasmic β -catenin expression in hepatocellular carcinomas with poor prognosis
Turato C, Vitale A, Fasolato S, *et al.*
British Journal of Cancer. 2014 May 27;110(11):2708-15.

Over-expression of SERPINB3 in hepatoblastoma: a possible insight into the genesis of this tumour?
Turato C, Buendia MA, Fabre M, *et al.*
Eur J Cancer. 2012 May;48(8):1219-26. doi: 10.1016/j.ejca.2011.06.004.

SERPINB3 modulates TGF-beta expression in chronic liver disease.
Turato C, Calabrese F, Biasiolo A, *et al.*
Lab Invest. 2010 Jul;90(7):1016-23. doi: 10.1038/labinvest.2010.55.

Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease.
Turato C, Ruvoletto MG, Biasiolo A, *et al.*
Dig Liver Dis. 2009 Mar;41(3):212-6. doi: 10.1016/j.dld.2008.06.001. Epub 2008 Jul 25.